Tal Ori, Ben Shem Erez, Peled Ofri, Elyashiv Osnat, Levy Tally
E. Wolfson Medical Center, Holon, Sackler Medicine, Tel Aviv University, Holon, Israel.
J Palliat Care. 2023 Apr;38(2):184-191. doi: 10.1177/08258597221083418. Epub 2022 Feb 28.
To evaluate the symptoms of women with epithelial ovarian cancer (EOC) during their last admission before death and analyze invasive palliative management administered in relation to symptom control and survival.
MATERIALS & METHODS: A retrospective review of Israeli patients with EOC, primary peritoneal cancer (PPC) and tubal cancer, admitted to our department prior to death between 2008-2018. Basic palliative treatment was defined as administration of IV fluids, analgesics, oxygen, antiemetics, antibiotics and/or blood transfusions. Procedures regarded as invasive included: peritoneal or pleural fluid drainage; placement of an indwelling catheter, administration of total parenteral nutrition (TPN), chemotherapy and ventilation.
82 patients were included. Most suffered from weakness and fatigue, gastrointestinal complaints, pain and shortness of breath. 34 patients (41.5%) required only basic palliative treatment to alleviate their symptoms; however, in 48 patients (58.5%) invasive interventions were needed. Patients treated with invasive procedures were younger at death by almost 9 years (mean age of 65.73 ± 9.5 vs. 74.78 ± 9.8; p = 0.001). There were significantly more women with platinum sensitive disease in the invasive interventions group compared to the basic palliative care (60.42% vs. 32.35%; p = 0.012). No survival difference was found between the groups from diagnosis to death, relapse to death, last chemotherapy to death and last admission to death.
EOC patients suffer from high disease burden and multiple symptoms before death. We found that physicians tend to use more invasive care in dying younger patients. However, this aggressive treatment does not prolong survival. Futile treatments influencing quality of life should be avoided.
评估上皮性卵巢癌(EOC)女性患者临终前最后一次住院期间的症状,并分析为控制症状和延长生存期而采取的侵入性姑息治疗措施。
对2008年至2018年间在我院临终前住院的以色列EOC、原发性腹膜癌(PPC)和输卵管癌患者进行回顾性研究。基本姑息治疗定义为静脉输液、镇痛药、氧气、止吐药、抗生素和/或输血治疗。侵入性操作包括:腹腔或胸腔积液引流;留置导管;全胃肠外营养(TPN);化疗;通气。
共纳入82例患者。大多数患者有虚弱、疲劳、胃肠道不适、疼痛和呼吸急促等症状。34例患者(41.5%)仅需基本姑息治疗来缓解症状;然而,48例患者(58.5%)需要侵入性干预。接受侵入性操作的患者死亡时年龄比未接受侵入性操作的患者小近9岁(平均年龄分别为65.73±9.5岁和74.78±9.8岁;p=0.001)。与基本姑息治疗组相比,侵入性干预组铂敏感疾病的女性患者明显更多(60.42%对32.35%;p=0.012)。两组从诊断到死亡、复发到死亡、最后一次化疗到死亡以及最后一次住院到死亡的生存期无差异。
EOC患者临终前疾病负担重,症状多样。我们发现医生倾向于对较年轻的临终患者采用更多的侵入性治疗。然而,这种积极的治疗并不能延长生存期。应避免采用影响生活质量的无效治疗。